Twinaqt Dolutegravir Lamivudine Tablet

Q1: What is Twinaqt (Dolutegravir + Lamivudine) used for?

Twinaqt is a two-drug simplified HIV regimen combining Dolutegravir 50mg (INSTI) + Lamivudine 300mg (NRTI). This dual-therapy approach is an evidence-based alternative to triple therapy for virologically suppressed adults, reducing drug exposure while maintaining suppression.

Q2: Is two-drug HIV therapy as effective as triple therapy?

The GEMINI-1 and GEMINI-2 clinical trials demonstrated that Dolutegravir + Lamivudine achieved equivalent viral suppression (HIV RNA <50 copies/mL) to Dolutegravir + TDF/FTC at 96 weeks in treatment-naive patients without pre-existing resistance mutations.

Q3: Who is Twinaqt suitable for?

Twinaqt is suitable for: treatment-naive adults without resistance mutations, no HBV co-infection (Lamivudine monotherapy risks HBV resistance), and no active hepatitis B (requires TDF-containing regimens). It is not recommended for patients with HIV-2 co-infection.

Q4: How is Twinaqt taken?

Take one tablet once daily at a consistent time. Can be taken with or without food. Antacids, iron, and calcium should be separated by at least 2 hours from dosing (due to Dolutegravir's interaction with multivalent cations).

Q5: What are the most common side effects?

Insomnia and headache (from Dolutegravir), mild nausea, and diarrhea are most common. Neuropsychiatric effects (anxiety, mood changes, vivid dreams) affect a minority of patients.

Q6: Why is HBV status critical before starting Twinaqt?

Lamivudine alone is insufficient for chronic hepatitis B treatment — it rapidly selects for M204V/I resistance in HBV. Patients with HBV co-infection MUST use a TDF or TAF-containing regimen. Twinaqt is contraindicated in HBV-co-infected patients.

Q7: What is the drug interaction concern with Dolutegravir?

Dolutegravir interactions: rifampicin/efavirenz require dose increase to 50mg twice daily; antacids/iron/calcium reduce absorption (separate by 2+ hours); metformin levels increase significantly. Comprehensive review before starting is essential.

Q8: What monitoring is required on Twinaqt?

CD4 and viral load at baseline, then 4–8 weeks, then every 3–6 months. Serum creatinine may increase slightly (not true kidney damage — Dolutegravir inhibits tubular creatinine secretion). Liver function at baseline and periodically.

Q9: Can Twinaqt be used during pregnancy?

Dolutegravir is now recommended throughout pregnancy. Lamivudine is safe in pregnancy. However, pregnant women with HBV co-infection require a TDF-containing regimen instead of Twinaqt. Manage with HIV/OB specialist.

Q10: What happens if Twinaqt virologically fails?

Virological failure requires genotypic resistance testing before switching. The clinical guidance for DTG + 3TC failure is evolving. Early detection through regular viral load monitoring is essential for preventing resistance accumulation.

Q11: How should Twinaqt be stored?

Store at room temperature away from light and moisture. Keep in original packaging out of reach of children.

Q12: Do I need a prescription for Twinaqt?

Yes. Twinaqt requires specialist HIV prescribing with HBV co-infection exclusion, resistance testing, and regular viral load monitoring.